Opinion

Video

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

Rationale for Ultra-Low PSA Threshold Analysis

Key Themes:

  • Post hoc analysis focusing on PSA response thresholds
  • Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
  • PSA as a surrogate biomarker in advanced prostate cancer

Expert Insights:

  • Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.

The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.